The trajectory of companies tied to flagship drugs like Viagra presents a challenging investment picture. While the initial boom of copyright, fueled by Viagra's extraordinary popularity, generated substantial wealth , the expiry in key regions has introduced considerable uncertainty . Investors are now facing the effect of rival medications , shri